Amy Broidrick Biography and Net Worth

Ms. Broidrick held key roles in the successful worldwide launches and life cycle marketing of blockbuster drugs including Zetia™, VYTORIN™, and Celebrex™, and specialty brands. Since 2016, she served as Senior Vice President, Head of Corporate Development at Viking Therapeutics, responsible for building and implementing the US and global corporate and business development functions. Before that, she was Vice President, Head of Global Marketing Excellence and Business Innovation with EMD Serono, Inc, part of Merck KGaA (Germany), where she led global and country brand and launch planning, and strategic transformation initiatives. Ms. Broidrick was Vice President, Head of Marketing and Commercialization at Arena Pharmaceuticals, where she oversaw commercialization planning for a first-in-class obesity drug, and also led Portfolio Planning. Before Arena, she held roles of increasing responsibility at Merck & Co. and Pfizer (formerly GD Searle) including Global Brand Leader with P&L accountability. She led Merck & Co.’s new products marketing planning across brands and pipeline for the Asia Pacific region. Ms. Broidrick holds a BA from Fairleigh Dickinson University, completed further undergraduate studies at Wroxton College in England, and performed post-graduate work at Fairleigh Dickinson.